Wells Fargo last night downgraded Pliant Therapeutics (PLRX) to Equal Weight from Overweight with a price target of $4, down from $41. The “unexpected pause” in enrollment following the Data and Safety Monitoring Board recommendation adds too much uncertainty on the path forward, the analyst tells investors in a research note. The firm says investors will likely write off bexotegrast in the near term, and safety may persist as an overhang on the program.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on PLRX:
- Pliant Therapeutics downgraded to Neutral from Buy at Citi
- Pliant Therapeutics Faces Uncertainty Amid BEACON-IPF Trial Pause: Analyst Downgrades to Neutral/High Risk
- Pliant Therapeutics downgraded to Equal Weight from Overweight at Wells Fargo
- Pliant Therapeutics trading resumes
- Pliant Therapeutics pauses enrollment, dosing in BEACON-IPF Phase 2b trial